Adela Mattiazzi

Dr. Adela Mattiazzi

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
Gaetano CiancioGaetano Ciancio
Gaetano Ciancio
GBGeorge William Burke
George William Burke
KSKiliana Suzart
Kiliana Suzart
AMAdela Mattiazzi
Adela Mattiazzi
AVAnil Vaidya
Anil Vaidya
JMJoshua Miller
Joshua Miller
Limited data are available on the use of tacrolimus and mycophenolate mofetil in conjunction with anti‐IL‐2 receptor antibody, in groups of kidney transplant recipients considered to be at higher ri...

1 February 2017 in Transplant Immunology
Verified
Journal Article
Closed access
Gaetano CiancioGaetano Ciancio
Gaetano Ciancio
JGJeffrey Gaynor
Jeffrey Gaynor
GGGiselle Guerra
Giselle Guerra
JSJunichiro Sageshima
Junichiro Sageshima
DRDavid Roth
David Roth
GBGeorge William Burke
George William Burke

1 May 2019 in Patient Education and Counseling
Verified
Journal Article
Closed access
JCJayanthi Chandar
Jayanthi Chandar
DLDavid A. Ludwig
David A. Ludwig
JAJuan Aguirre
Juan Aguirre
AMAdela Mattiazzi
Adela Mattiazzi
MBMalgorzata Bielecka
Malgorzata Bielecka
ADAlan M. Delamater
Alan M. Delamater

28 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JGJeffrey Gaynor
Jeffrey Gaynor
GGGiselle Guerra
Giselle Guerra
DRDavid Roth
David Roth
LCLinda Chen
Linda Chen
WKWarren Kupin
Warren Kupin
Gaetano CiancioGaetano Ciancio
Gaetano Ciancio
Background: We previously reported that graft failure due to nonadherence (GFNA) was a major cause of graft loss in kidney transplantation. Here, among 150 prospectively-followed kidney transplant recipients at 18 years post-transplant, we provide: updated (longer-term) estimates of cause-specific graft loss probabilities, risk factors for developing GFNA, and detailed characterizations of patients’ overt nonadherent (NA) behavior, including timing, extent, and clinical consequences. Methods: Determination of the patient becoming NA in taking his/her immunosuppressive medications, and the underlying cause of graft loss, were determined prospectively by the attending physicians. For never-functioning-graft, GFNA, GF due to causes other than NA (Other GF), and death with a functioning graft (DWFG), cumulative incidence functions were used to estimate the cumulative probabilities of cause-specific graft loss. Cox stepwise regression was used to determine significant multivariable predictors for the hazard rate of developing GFNA. Results: GFNA was a major cause of graft loss (22/150 patients), particularly among African-American and Hispanic recipients <50 years of age-at-transplant (20/56 experienced GFNA), with estimated percentages of such patients ever developing GFNA ranging between 36.9 and 41.5%. These patients were also at a higher risk of developing Other GF. For the remaining patients (2/94 experienced GFNA), estimated percentages of ever-developing GFNA were much lower (range: 0.0–6.7%). The major cause of graft loss among recipients ≥50 years of age was DWFG; GFNA rarely occurred among older recipients. In 21/22 GFNA patients, NA behavior lasted continuously from the time of developing NA until GFNA. In total, 28/150 patients became NA, and 67.9% (19/28) occurred beyond 36 months post-transplant. A total of 25 of 28 NA patients (89.3%) developed biopsy-proven acute rejection and/or chronic rejection that was directly attributed to the NA behavior. Lastly, 25/28 admitted to NA behavior, with financial and psychological components documented in 71.4% (20/28) and 96.4% (27/28) of NA cases, respectively. Conclusions: These results highlight the importance of performing serial monitoring of patients for overt NA behavior throughout their post-transplant follow-up. Financial and psychological components to NA behavior need to be simultaneously addressed with the goal of achieving complete avoidance/elimination of NA behavior among higher risk patients.

23 August 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
AMAdela Mattiazzi
Adela Mattiazzi
CCCamilo A. Cortesi
Camilo A. Cortesi
RPRhea J. Patil
Rhea J. Patil
KMKarla G. Carias Martinez
Karla G. Carias Martinez
MSMai Sedki
Mai Sedki
GGGiselle Guerra
Giselle Guerra
Key Points: Ultrasound-guided kidney transplant biopsy is considered safe, with similar complications rates regardless of the performing team. Besides well-known risk factors for complications, we found that sex and race are also predictors. The performance of kidney transplant biopsy remains an integral part of nephrology training. Background: Kidney transplant biopsies are the gold standard for evaluating allograft dysfunction. These biopsies are performed by nephrologists and radiologists under real-time ultrasound guidance. A few studies have examined the outcomes of ultrasound-guided kidney transplant biopsy in transplant recipients; however, none have compared these outcomes between both specialties. Methods: We retrospectively analyzed a cohort of 678 biopsies performed in a single center during a 44-month study period. Biopsies were stratified into two groups based upon the specialist performing the procedure: interventional radiology (IR; N=447) and transplant nephrology (TN; N=231). Results: There were 55 (8%) complications related to biopsies in the entire cohort: 37 (8.2%) in the IR group and 18 (7.7%) in the TN group, without statistical difference between the groups (P=0.94). Blood pressure control and prior use of anticoagulation were significant predictors of complicated biopsies (P=0.004 and 0.02, respectively). Being a woman and prior use of anticoagulation were significant predictors of transfusion of blood products (P=0.01 and 0.01, respectively). Being a woman and blood pressure control were significant predictors of overall perinephric hematoma (P=0.01 and 0.01, respectively), and Black race was a significant predictor of perinephric hematoma without worsening of renal function (P=0.005). The specialist team performing the procedure was not a statistically significant predictor of biopsy complications, transfusion of blood products, or perinephric hematoma with comparable sample yield. Conclusions: Percutaneous ultrasound-guided kidney transplant biopsy performed by transplant nephrologists have similar complication rates when compared with interventional radiologists in an academic center.

10 October 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
Gaetano CiancioGaetano Ciancio
Gaetano Ciancio
JGJeffrey J. Gaynor
Jeffrey J. Gaynor
GGGiselle Guerra
Giselle Guerra
MTMarina M. Tabbara
Marina M. Tabbara
DRDavid Roth
David Roth
GBGeorge W. Burke
George W. Burke
More favorable clinical outcomes with medium‐term follow‐up have been reported among kidney transplant recipients receiving maintenance therapy consisting of “reduced‐tacrolimus (TAC) dosing,” mycophenolate mofetil (MMF), and low‐dose corticosteroids. However, it is not clear whether long‐term maintenance therapy with reduced‐calcineurin inhibitor (CNI) dosing still leads to reduced renal function. A prospectively followed cohort of 150 kidney transplant recipients randomized to receive TAC/sirolimus (SRL) versus TAC/MMF versus cyclosporine microemulsion (CSA)/SRL, plus low‐dose maintenance corticosteroids, now has 20 years of post‐transplant follow‐up. Average CNI trough levels over time among patients who were still alive with functioning grafts at 60, 120, and 180 months post‐transplant were determined and ranked from smallest‐to‐largest for both TAC and CSA. Stepwise linear regression was used to determine whether these ranked average trough levels were associated with the patient's estimated glomerular filtration rate (eGFR) at those times, particularly after controlling for other significant multivariable predictors. Experiencing biopsy‐proven acute rejection (BPAR) and older donor age were the two most significant multivariable predictors of poorer eGFR at 60, 120, and 180 months post‐transplant (p < 000001 and 0.000003 for older donor age at 60 and 120 months; p = 0.00008 and 0.70). Long‐term maintenance therapy with reduced‐CNI dosing does not appear to cause reduced renal function.